Clinical Trial Update: Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM [Phase 4]

View source ↗

Summary

Phase 4 trial comparing basal insulin glargine in combination with exenatide twice daily versus insulin aspart in type 2 diabetes mellitus; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Aspart 30 (insulin aspart)
• Basal insulin glargine in combination with exenatide bid

Snippet

Sponsor: Huazhong University of Science and Technology | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED